Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haizheng chimeric anti-CD20 mAb in relapsed indolent CD20-positive B-cell NHL (Phase I/II)
CTR20160456Phase 2Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started Aug 2016; status: completed.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20160456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160456.